Європейський Союз - латвійська - EMA (European Medicines Agency)

chiesi farmaceutici spa - kofeīna citrāts - apnojas - psychoanaleptics, - Ārstēšana primārās apnoea priekšlaicīga jaundzimušajiem.

Європейський Союз - латвійська - EMA (European Medicines Agency)

astrazeneca ab - saksagliptīns - cukura diabēts, 2. tips - cukura diabēts - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Європейський Союз - латвійська - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Європейський Союз - латвійська - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Європейський Союз - латвійська - EMA (European Medicines Agency)

janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibakteriālas līdzekļi sistēmiskai lietošanai, - doribax ir indicēts, lai ārstētu šādu infekciju pieaugušajiem:hospitālās pneimonija (ieskaitot ventilators, kas saistītas ar plaušu karsoni);sarežģīta iekšējai-vēdera dobuma infekcijas;komplicēta urīnceļu infekcijas. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.

Європейський Союз - латвійська - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):ārstēšanu, hiv-1 infekcijas antiretrovirālo terapiju (art)-pieredzējuši pieaugušiem pacientiem, ieskaitot tos, kas ir bijis ļoti pirmapstrāde. par attieksmi pret hiv-1 infekcijas pediatrijas pacienti vecumā no 3 gadiem un vismaz 15 kg ķermeņa svara. pieņemot lēmumu uzsākt ārstēšanu ar darunavir co-vienīgi ar mazu devu ritonavir, būtu rūpīgi jāapsver ārstēšanas vēsturi individuāla pacienta un modeļiem, kas mutāciju, kas saistīti ar dažādām aģentu. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 un 5. darunavir co-vienīgi ar mazu devu ritonavir ir norādīts kombinācijā ar citām pretvīrusu zālēm, lai ārstētu pacientus ar cilvēka imūndeficīta vīrusu (hiv-1) infekcija.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. pieņemot lēmumu uzsākt ārstēšanu ar darunavir, šādu mĀkslas pieredzējuši pacientiem, genotypic testēšana būtu ceļvedis, lietošanas darunavir (skatīt 4. 2, 4. 3, 4. 4 un 5.

Європейський Союз - латвійська - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevīrs - c hepatīts, hronisks - pretvīrusu līdzekļi sistēmiskai lietošanai - victrelis indicēts hroniska hepatīta c (chc) genotipu 1 infekcija, kombinācijā ar peginterferon alfa un ribavirīnu pieaugušiem pacientiem ar apmaksātiem aknu slimība, kuri iepriekš neapstrādātus vai kuri nav iepriekšējās terapijas ārstēšanas.

Європейський Союз - латвійська - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Європейський Союз - латвійська - EMA (European Medicines Agency)

pfizer europe ma eeig - tigeciklīns - bacterial infections; skin diseases, bacterial; soft tissue infections - antibakteriālas līdzekļi sistēmiskai lietošanai, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas. lietderīgi izmantot antibakteriālas vielas.

Європейський Союз - латвійська - EMA (European Medicines Agency)

accord healthcare s.l.u. - tigeciklīns - soft tissue infections; intraabdominal infections; bacterial infections; skin diseases, infectious - antibakteriālas līdzekļi sistēmiskai lietošanai, - tygecycline accord ir norādīts pieaugušajiem un bērniem, kas vecāki par astoņiem gadiem, par attieksmi pret šādām infekcijām (skatīt 4. 4 un 5. 1):sarežģītu ādas un mīksto audu infekcijas (cssti), izņemot diabēta pēdu infekciju (skatīt 4. iedaļu. 4)sarežģīta iekšējai-vēdera infekcijām (ciai)tygecycline vienojoties, ir jāizmanto tikai situācijās, kad citas alternatīvas antibiotikas nav piemērotas (skatīt 4. 4, 4. 8 un 5. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.